Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Why Scarce Automobile Supply Will Not Lift Lucid Group Stock

By Chris Lau, InvestorPlace Contributor

Lucid has yet to sell a vehicle, leaving speculators to bet on the stock price relative to Tesla, a trade that will prove too risky.

Palantir Stock Could Be Ready to Rally Significantly From These Levels

By Chris Lau, InvestorPlace Contributor

Palantir a fan favorite for technology investors who bet the Foundry platform will lead to customer contracts worth over $100 million.

DiDi Global Stock Is a Great Buy Here If You Can Handle the Regulation Risk

By Chris Lau, InvestorPlace Contributor

DIDI is a gamble worth considering after sellers sold the stock on the way down, creating a bottom in the stock recently.

Cassava Stock Is a Bold Play That Could Pay Off Soon

By Chris Lau, InvestorPlace Contributor

Bears are attacking Cassava as it questions the quality of its clinical data and try to stop its study for treating Alzheimer’s disease.

7 Small-Cap Stocks That Are Diamonds in the Rough

By Chris Lau, InvestorPlace Contributor

Small-cap stocks have more upside when investors ignore them, leaving a wide mispricing and a discount big enough for investors. Here are the seven most under-followed companies with the biggest potential upside ahead.

Load More